Table 2.
Redox biomarkers of patients included into a study with comparison of study groups. Variables are shown as medians with lower and upper quartiles where appropriate.
| Ischaemic (n = 479) | Nonischaemic (n = 295) | p value | |
|---|---|---|---|
| TAC (mmol/l) | 1,14 (1,04-1,26) | 1,11 (0,98-1,22) | 0,001 |
| TOS (mmol/l) | 4,75 (4-6,1) | 5,10 (4,3-6,2) | NS |
| OSI (TOS/TAC) | 4,27 (3,31-5,65) | 4,60 (3,68-5,89) | 0,01 |
| Uric acid (μmol/l) | 407,0 (333,0–505,0) | 413,0 (326,0-506,0) | NS |
| Uric acid (μmol/l) XOi (-) | 406,0 (336,0–491,0) | 423,5 (344,5–497,5) | NS |
| Uric acid (μmol/l) XOi (+) | 410,5 (324,0–541,0) | 403,0 (308,0–519,0) | NS |
| Bilirubin (μmol/l) | 12,70 (9,20-19,10) | 15,40 (10,60-21,90) | 0,001 |
| Albumin (g/l) | 42,00 (39,00–44,00) | 42,00 (39,00–45,00) | NS |
| PSH (μmol/g of protein) | 4,10 (3,1-5,1) | 4,75 (3,65-5,6) | 0,001 |
| MDA (μmol/l) | 1,80 (1,40-2,20) | 1,70 (1,40-2,10) | 0,05 |
| MDA/PSH ratio | 0,435 (0,314-0,647) | 0,358 (0,269–0,527) | 0,001 |
TAC: total antioxidant capacity; TOS: total oxidant status; OSI: oxidative stress index; MDA: malondialdehyde; PSH: sulfhydryl groups; XOi: xanthine oxidase inhibitors; NS: nonsignificant.